Literature DB >> 21484693

[Head and neck cancer of aircrew personnel in aeronautical medical expertise].

Anissa Sethom1, Samir Ben Salem, Imededdine Ben Dhia, Ali Mrabet, Amel Souissi, Ibtissem Dkhil, Faouzi Mehdi, Riadh Allani, Rim Bouattour, Touhami Khelifi, Chokri Ben Othmen, Nabil Guermazi, Mohamed Kamel Chebbi.   

Abstract

BACKGROUND: ENT cancers due to their location and treatment encompass a number of physical symptoms related to swallowing and communication disorders. AIM: To evaluate flight capacity of aircrew personnel with ENT cancer and consequences on fitness and waiver criteria. CASES REPORT: Case 1: A 52 years old smoker pilot whish present laryngeal epidermoid carcinoma staged T3M0N0 and treated by total laryngectomy with curative radio-therapy (70Gy). Metastasis occurred on lumgth and death heaped after acute respiratory failure. Case 2: A 55 years old mechanic whish had rhinopharyngeal undifferentiated carcinoma staged T4N2M0 and treated with radiochemotherapy with favourable follow-up. Inability for flight was proclaimed because of severe psychological impact. Case 3: Concerned a vesiculograpillary carcinoma of thyroid gland occurring in a 46 years old helicopter pilot. After total thyroidectomy and iodine treatment, the patient has obtained complete fitness to flight.
CONCLUSION: Fitness to flight can be controversed in ENT cancer occurs. Epidemio-clinical paraclinical, functionnel and operational criterias must be considered when wainer to be proclaimed.

Entities:  

Mesh:

Year:  2011        PMID: 21484693

Source DB:  PubMed          Journal:  Tunis Med        ISSN: 0041-4131


  1 in total

Review 1.  The risk of melanoma in airline pilots and cabin crew: a meta-analysis.

Authors:  Martina Sanlorenzo; Mackenzie R Wehner; Eleni Linos; John Kornak; Wolfgang Kainz; Christian Posch; Igor Vujic; Katia Johnston; Deborah Gho; Gabriela Monico; James T McGrath; Simona Osella-Abate; Pietro Quaglino; James E Cleaver; Susana Ortiz-Urda
Journal:  JAMA Dermatol       Date:  2015-01       Impact factor: 10.282

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.